AstraZeneca

July 18, 2023

The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer and Merck

Illumina Inc., in collaboration with Nashville Biosciences LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, have announced the five founding new members of the Alliance for Genomic Discovery.

By VUMC News and Communications
November 10, 2022

AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17

On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.

By Bill Snyder
Shown here is the research team that discovered monoclonal antibodies that protect against COVID-19 in high-risk individuals.
August 24, 2022

COVID antibody research conducted at VUMC lands national award

A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine.

By Bill Snyder
Cody Stubblefield, RN, gives the first of two injections of an antibody combination to Caroline Davis to protect her from COVID-19.
December 23, 2021

Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness

On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.

By Bill Snyder
December 9, 2021

Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization

The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which  protects against COVID-19, discovered last year at Vanderbilt University Medical Center.

By Bill Snyder
December 2, 2021

Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms

By Bill Snyder
October 28, 2021

VICC’s Mayer departing to take new role with AstraZeneca

Ingrid Mayer, MD, MSCI, is departing Vanderbilt University Medical Center for a new role as an executive with AstraZeneca.
By Tom Wilemon
October 5, 2021

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.
By Bill Snyder
August 20, 2021

COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study

A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
By Bill Snyder
April 6, 2021

U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC

The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.
By Bill Snyder
October 13, 2020

COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials

AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.
By Bill Snyder
June 9, 2020

Vanderbilt, AstraZeneca collaborate on new COVID-19 antibody research

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.
By Bill Snyder
April 8, 2020

Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments

Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.
By Bill Snyder